BioSpace News Archive

Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral. I

$20 Million Memorandum of Understanding completed with an investor for a strategic upmarket transaction $10 Million financing proposal in the same MOU for the acquisition of infectious disease and cancer diagnostics company awaiting EUA approval from FDA for COVID-19 rapid diagnostic assay system ALTuCELL acquisition update NuGenHealth SaaS Remote Patient Monitoring and Chronic Care Management 50% Partnership Completed a Memorandum of Understanding Regarding Development partnership for Ii-Ke

Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, points to its role in taking a patient-first approach for providing personalized medicine as a more precise basis to predict the prognosis of genetic diseases.

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that its subsidiary Primus Corporation has received a warning letter from the U.S. Food and Drug Administration (FDA) following an inspection of its Kansas City, Missouri manufacturing facility that took place in January 2020. The issues identified in this letter primarily relate to th

OncoSec Medical Incorporated announced that in connection with its previously announced offering of common stock, it has entered into purchase agreements for the purchase of an aggregate 4,608,589 shares of the Company at an offering price of $3.25 per share for aggregate gross proceeds of approximately $15 million, before placement agent fees and other offering expenses.

A recent report by Transparency Market Research states that the global cardiac holter monitor market is projected to grow substantially in the duration of 2016 to 2024.

Knee implants plays significant role in resurfacing a knee damaged either by traumas or by rheumatoid arthritis.

The global personalized LASIK surgery market features a highly consolidated vendor landscape along with intense competition among a few established players.

The ophthalmic lasers market reached an evaluation of $0.97 bn in 2015. According to a newly released TMR report, the market promises further growth at 4.60% CAGR during 2016-2024, and reach US$1.44 bn in evaluation by 2024 end.

On an upward growth trajectory, the global microfluidics market will chart a double digit growth over the forecast period of 2017 to 2025.